secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2022-01-12T23:59:59+00:00
Accession:  0001493152-22-001044
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma reports IMX-110 50% response rate in STS mouse study, beating standard of care
--------------------------------------------------------------------------------

- IMX-110 as monotherapy achieved 50% response rate in first-line-therapy-resistant STS mouse study, vs 0% for doxorubicin.
- Study assessed by RECIST 1.1 criteria after one cycle; funded by Immix and conducted by major STS oncology center.
- IMX-110 has FDA orphan drug designation for STS and rare pediatric disease designation for rhabdomyosarcoma.
- Global STS market estimated $2.9B in 2019, projected to reach $6.5B by 2030.
- Prior clinical data showed median PFS of 4 months with zero drug-related severe adverse events in heavily pretreated patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222001044/0001493152-22-001044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222001044/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-001044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer